Search
Immatics NV
IMTXAdd to Watchlist
9.857USD
+0.007+0.07%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Immatics NV is 8.83, ranking 48 out of 387 in the Biotechnology & Medical Research industry. The average price target is 17.50, with a high of 25.00 and a low of 11.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
18.578
Target Price
+94.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Immatics NV
IMTX
11
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Immatics NV's expected revenue for the next quarter?
Immatics NV's expected revenue is 11.99M.
What is Immatics NV's price target?
Analysts forecast that Immatics NV's price target is USD 17.50, with the highest forecast at USD 25.00 and the lowest forecast at USD 11.00.
How have Immatics NVIMTX's recent earnings per share performed?
The market expectation was USD -0.50, while Immatics NVIMTX's earnings per share (EPS) for the previous quarter was USD -0.35. EPS for the next quarter is expected at USD -0.49.
What is the analyst rating for Immatics NV?
Based on the ratings of Immatics NV's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.